Quantitative Testing for Drugs of Abuse:

Quantitative Testing for Drugs of Abuse is the quantitative level of a positive drug screen that specifically indicates whether a drug or a drug indicator was detected in the donor’s system at the time of collection.

Genetic Testing:

Genetic testing is the analysis of human DNA, RNA or chromosomes in order to detect heritable disease-related genotypes, mutations, phenotypes or karyotypes for clinical purposes. Such purposes include predicting risk of disease, identifying carriers, establishing prenatal and clinical diagnosis or prognosis.

Superior HealthPlan requires prior authorization as a prerequisite for payment for some services, including Drugs of Abuse and Genetic/Molecular Diagnostic Testing.

It is the ordering provider’s responsibility to request prior authorization for Genetic/Molecular Diagnostic Testing and Quantitative Drugs of Abuse. Failure to obtain an authorization for a service requiring a prior authorization will result in a denial of payment.

Please visit www.SuperiorHealthPlan.com for a list of Drugs of Abuse and Genetic/Molecular Diagnostic Testing procedure codes that require prior authorization.

Requesting prior authorization is easy. Requests can be done by:

- Submitting an authorization through the Secure Web Portal. Providers must be registered to access the Secure Web Portal and can register at www.SuperiorHealthPlan.com under Provider Resources, then Secure Web Portal.
- Faxing an authorization request to the appropriate fax number by product. The fax form can be found on the website at www.SuperiorHealthPlan.com under Provider Resources, then Forms.
- Calling Medical Management at 1-800-218-7508.

Information needed to submit request for prior authorization:

- CPT Code
- Diagnosis Code
- Rendering laboratory Provider’s name
- Supporting documentation